- ADJUNCT ASSOCIATE PROFESSOR Medicine, Infectious Diseases
In the News
Dr. Calfee discusses tick-borne disease in The Daily News feature The Daily Check Up.
View the PDF.
Prevention and treatment of healthcare-acquired infections, antibiotic resistance, and hospital epidemiology/infection control
Morgan DJ, Weisenberg SA, Augenbraun M, Calfee DP, Currie BP, Furuya EY, Holzman RG, Montecalvo MA, Phillips M, Polsky B, Sepkowitz K. Multidrug resistant Acinetobacter baumannii in New York City - 10 years into the epidemic. Infect Control Hosp Epidemiol 2009; 30(2): 196-197.
Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29(12): 1099-1106.
Calfee DP, Salgado CD, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Saint S, Weinstein RA, Wise R, Yokoe DS. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(S1): S62-S80.
Cohen AL, Calfee DP, Fridkin SK, Huang SS, Jernigan JA, Lautenbach E, Oriola S, Ramsey KM, Salgado SD, Weinstein RA. Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC position paper. Infect Control Hosp Epidemiol 2008; 29(10): 901-913.
Calfee DP, Jenkins SG. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae among intensive care unit patients. Infection Control Hosp Epidemiol 2008; 29(10): 966-968.
Calfee DP. Clostridium difficile: A reemerging pathogen. Geriatrics 2008; 63(9): 10-14, 21.
Calfee DP, Kornblum J, Jenkins SG. A pseudo-outbreak of Bordetella bronchiseptica infections associated with contaminated rabbit blood used as a microbiology culture medium supplement. Infect Control Hosp Epidemiol 2007; 28: 758-760.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Calfee has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor Infection Control Room Room L2-16
1425 Madison Avenue
New York, NY 10029